Mepacrine in recalcitrant cutaneous lupus erythematosus: Oldfashioned or still useful?

11Citations
Citations of this article
10Readers
Mendeley users who have this article in their library.

Abstract

Treatment of recalcitrant cutaneous lupus erythematosus (CLE) is challenging. In situations where conventional treatment approaches fail mepacrine – an antimalarial/ antiinflammatory drug that has fallen into oblivion in the last decades – might still be a promising option. We retrospectively analysed medical records of 10 patients with refractory CLE that were treated with mepacrine (100–200 mg/day) as mono- or combination therapy for various time intervals between 2001 and 2013 at the University Hospital Würzburg. Mepacrine was generally well tolerated. Side effects were mild and usually resolved after reduction or cessation. Over 50% of the patients experienced amelioration of their symptoms despite a previously recalcitrant clinical course. Altogether, our data demonstrate that mepacrine still remains a useful and effective therapeutic option for otherwise treatment- resistant CLE.

Cite

CITATION STYLE

APA

Benoit, S., & Goebeler, M. (2015). Mepacrine in recalcitrant cutaneous lupus erythematosus: Oldfashioned or still useful? Acta Dermato-Venereologica, 95(5), 596–599. https://doi.org/10.2340/00015555-2031

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free